21 results about "Eb virus" patented technology

The invention belongs to the technical field of biological genetic engineering, and particularly relates to a mouse model construction scheme capable of reproducing a key phenotype of hemophagocytic syndrome, which comprises the following steps: inserting a loxP-STOP-loxP-LMP1 conditional expression cassette into a Rosa26 safe port site in a fixed point manner to obtain an Lmp1cKI mouse strain; and hybridizing the mouse with an Ncr1-Cre transgenic mouse of NK cell specific expression Cre recombinase. In a double transgenic offspring (Lmp1Ncr1-Cre), STOP fragments are cut off by Cre enzyme, and continuous high expression of EB virus LMP1 protein in NK cells is driven. The model does not need chemical induction or immune intervention, and typical hemophagocytic syndrome phenotypes, namely serum IL-6, TNF-alpha and IFN-gamma, spontaneously appear within 7-9 days after young rats are born; the body weight is reduced and the survival rate is obviously reduced; the proportion of lymphocytes is sharply reduced; and NK cells are depleted. The invention provides a stable and reliable tool for hemophagocytic syndrome pathogenesis research, drug screening and treatment evaluation.

The invention relates to a detection kit for nasopharynx cancer diagnosis and screening, which comprises an immunochromatography detection card, and the immunochromatography detection card comprises a reagent for detecting EB virus antigen and antibody through a colloidal gold labeling method. The invention also relates to application of the detection card and the EB virus antigen-antibody in preparation of a detection kit or a detection card for nasopharynx cancer diagnosis and screening.

The application belongs to the technical field of antibodies, and discloses a monoclonal antibody Fab5 for recognizing EB virus gB protein and application thereof. The monoclonal antibody or antigen-binding fragment thereof has high affinity to the gB protein and can significantly inhibit the infection of EBV on epithelial cells and B cells, and the epitope of the Fab5 binding to the gB is determined through structural analysis. The antibody can be used for detecting the presence or level of the gB protein in a sample, detecting the EB virus, diagnosing diseases caused by the EB virus infection, preventing the EB virus infection and / or treating and / or preventing diseases caused by the EB virus infection.

The invention relates to the technical field of biology, in particular to an anti-EB (Epstein-Barr) virus Rta protein antibody as well as an antigen binding fragment and application thereof. The invention provides an antibody capable of specifically recognizing EB (Epstein-Barr) virus Rta protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises complementary determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, and the amino acid sequences of the complementary determining regions are respectively as follows: GFTFSSSYG, ISSSRYT, ARHLLSGTSSFDC, KSLHSNGNTY, YMS and MQSLEYPFT. The antibody or the antigen binding fragment thereof can be used as a positive control and a calibrator in a nasopharyngeal carcinoma in-vitro diagnostic kit, so that the problem of batch-to-batch difference existing in nasopharyngeal carcinoma positive serum is avoided, and the production cost of the nasopharyngeal carcinoma detection kit is reduced.

The invention relates to a kit for early differential diagnosis of EBV-HLH and a method for auxiliary diagnosis of EBV-HLH. The kit comprises an EBV nucleic acid detection reagent and a miRNA-375 detection reagent. The kit provided by the invention is used for combined detection of EBV-DNA and miRNA-375 in a detection sample, and when an EBV-DNA detection result is greater than 5000 copies / mL and a miRNA-375 detection CT value is less than 35, suspected EBV-HLH is diagnosed. The invention not only provides a specific diagnostic index for EB infected diseases, but also serves as a reliable auxiliary diagnostic tool for EBV-HLH and other EB virus infection related diseases. When the kit provided by the invention is used for identifying and diagnosing EBV-HLH, the sensitivity and the accuracy are higher.

The present application belongs to the field of medicine, and particularly relates to an EBNA1 inhibitor. The small molecule inhibitor recorded in the present application is proved by surface plasmon resonance (SPR) analysis to interact with EBNA1 in vitro and have high affinity, significantly inhibit the function of EBNA1 at the cell level, significantly down-regulate the copy number of the Epstein-Barr virus (EBV) genome of PBMC of a nasopharyngeal carcinoma patient in vitro, have good biological safety in mice, provide a new treatment strategy for patients with EB virus positive tumors, and have far-reaching clinical significance and popularization.

The invention discloses a 5E2-12 monoclonal antibody and application thereof, the 5E2-12 monoclonal antibody is specifically combined with EB virus nuclear antigen and comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, the amino acid sequences of VHCDR1, VHCDR2 and VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the amino acid sequences of VLCDR1, VLCDR2 and VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses a preparation method of the 5E2-12 monoclonal antibody. The invention also provides an antibody fragment of the 5E2-12 monoclonal antibody. The 5E2-12 monoclonal antibody provides a potential choice for research and development of clinical medicines for diagnosing and treating EBV latent infection and EB virus related tumors.

The invention belongs to the technical field of medical biology, and particularly relates to an EBV (Epstein-Barr Virus) neutralizing antibody-specifically-immune plasma high-throughput screening method and application thereof. EB virus envelope glycoprotein gp350 is selected as a screening target antigen, EBV specific plasma containing a high-titer EBV neutralizing antibody is rapidly screened in a high-throughput mode and used for preparing EBV specific human immune globulin, the titer of the EBV neutralizing antibody is obviously higher than that of listed intravenous gamma-C products, and the content of the EBV neutralizing antibody is about 4-8 times that of the EBV neutralizing antibody with the same concentration. The method provided by the invention can realize large-scale collection of EBV specific plasma through rapid high-throughput screening, reduces the workload of plasma screening, is suitable for large-scale production of EBV specific human immune globulin, and has a good application prospect.

Disclosed are a monoclonal antibody Fab5 recognizing the gB protein of EB viruses and the use thereof, belonging to the technical field of antibodies. The monoclonal antibody or an antigen-binding fragment thereof has high affinity for the gB protein and can significantly inhibit the EB virus infection of epithelial cells and B cells, and the epitope of the Fab5 binding to the gB is clarified by structural analysis. The antibody can be used for detecting the presence or level of the gB protein in specimens, detecting EB viruses, diagnosing diseases caused by EB virus infection, preventing EB virus infection, and / or treating and / or preventing diseases caused by EB virus infection.

The invention relates to a fusion immunogen and application thereof in preparation of a self-replicating mRNA vaccine infected by EBV, and belongs to the technical field of biological medicine. The fusion immunogen is composed of a signal peptide, an EB virus latency period protein, a linker and an MITD structure. The EB virus incubation period protein is selected from one or more of EBNA1, EBNA3A, LMP1 and LMP2. The fusion immunogen can be used for constructing a self-replicating mRNA vaccine, can induce an organism to generate specific humoral immunity and cellular immunity response, and is suitable for prevention and treatment of EBV related diseases.

The invention discloses an EB virus related B cell lymphoma diagnostic kit based on GNAS methylation detection. The invention provides a new marker for diagnosis of EB virus related B cell lymphoma, provides a matched and verified special detection primer, and performs functional reverse verification of 5-aza-2 '-deoxycytidine drug intervention. According to the invention, the potential value of the marker in the aspect of curative effect prediction is defined, and a possible molecular basis is provided for implementing individualized demethylation treatment clinically.

This invention relates to immunological detection, particularly to the field of immunological diagnosis of tumors. Specifically, this invention provides a method for diagnosing nasopharyngeal carcinoma based on anti-EBV antibody levels, and a kit for using said method. This invention also provides a polypeptide encoded by the EBV BNLF2b gene for the above-mentioned diagnosis and its use in the diagnosis of nasopharyngeal carcinoma.

The invention discloses a reagent and a kit for detecting EB (Epstein-Barr) virus infection and a method for detecting EB virus infected cell lineage, and belongs to the field of medical diagnosis. The technical problem to be solved by the invention is how to accurately locate different cell lineages of EBER + cells. The reagent for detecting EB virus infection disclosed by the invention contains an EBV probe and an antibody for marking a cell lineage, the sequence of the EBV probe is shown as SEQ ID No.1 and SEQ ID No.2, and the antibody for marking the cell lineage is a CD3 antibody, a CD20 antibody and / or a CD56 antibody. The reagent and the kit for detecting EB virus infection can be used for simultaneous marking of EBER genes and antigen proteins, accurate positioning of different cell lineages of EBER + cells is achieved, and cell lineage positioning of EB virus infection is further achieved.

The application belongs to the technical field of antibodies, and discloses a monoclonal antibody 5E9 for recognizing human R9AP protein and application thereof. The monoclonal antibody or antigen binding fragment thereof has high affinity to R9AP protein and can significantly inhibit EBV infection on epithelial cells and B cells. The antibody can be used for detecting the presence or level of R9AP protein in a sample, detecting diseases caused by high expression of R9AP, and preventing EB virus infection and / or treating and / or preventing diseases caused by EB virus infection.

The present invention relates to the technical field of antibodies. Disclosed are a monoclonal antibody 5E9 for recognizing a human R9AP and a use thereof. The monoclonal antibody or an antigen-binding fragment thereof has a high affinity to an R9AP and can significantly inhibit the infection of EB virus (EBV) on epithelial cells and B cells. The antibody can be used for detecting the presence or level of the R9AP in a sample, detecting diseases caused by high expression of the R9AP and preventing EBV infections and / or treating and / or preventing diseases caused by EBV infections.

The invention discloses a preparation method and application of a ZIF-8-EGCG / Co < 2 + >-coated ZnPc nano composite material. A ZIF-8 metal organic framework is used as a main body, EGCG, Co < 2 + > ions and a ZnPc photosensitizer are subjected to functional modification, and the EB virus targeted recognition capability and antibacterial activity of EGCG, the Fenton-like catalytic characteristic of Co < 2 + > and the photodynamic effect of ZnPc are further integrated on the basis of ensuring the remarkable surface area characteristic, the adjustable pore structure and the excellent biocompatibility of the composite material. Through an acid response trigger mechanism, directional enrichment and controllable release of drugs at tumor sites are realized, synergistically enhanced ROS is generated, tumor cell death is effectively induced, microbial colonization closely related to nasopharyngeal carcinoma occurrence and development is inhibited, and the drug effect is improved. An innovative solution is provided for overcoming the clinical challenges that a traditional operation is difficult to eradicate tiny focuses, and normal tissue damage is easily caused.

The invention provides EB (Epstein-Barr) virus nucleic acid detection primers, a probe and a kit, according to a target sequence of an EB virus gene, the sequences of the primers and the probe in an asymmetric primer ERA detection system are designed and screened, and the ratio of upstream and downstream primers and an amplification reaction system are optimized, so that the EB virus nucleic acid sequence can be specifically identified, and the EB virus nucleic acid detection kit has the advantages of high specificity and high sensitivity. Non-specific binding with other irrelevant nucleic acids is reduced, so that the detection specificity is improved; meanwhile, efficient amplification of EB virus nucleic acid is realized, and the EB virus nucleic acid can be accurately detected even under the condition that the content of the virus nucleic acid is extremely low, so that the detection sensitivity and the amplification efficiency are improved.

The invention discloses a one-pot EB virus nucleic acid detection method and device based on RPA-PfAgo, and belongs to the technical field of biological detection. The method comprises the following steps: physically isolating an RPA amplification system from a PfAgo cleavage reaction system in the same container, adding a sample to be detected, carrying out RPA amplification at 37-42 DEG C, heating to 85-96 DEG C, and releasing physical isolation to carry out PfAgo cleavage reaction. According to the method, isothermal amplification (RPA), specific nucleic acid recognition based on PfAgo and fluorescence readout are integrated in a single closed reaction tube, the reaction tube does not need to be opened, the pollution risk is remarkably reduced, rapid, sensitive and visual EBV detection is achieved, and the method is suitable for field detection, rapid virus detection in a resource limited environment and nucleic acid detection application of other similar pathogens.

The application discloses an EB virus antigen of a chimeric design and application thereof. The EB virus chimeric antigen provided by the application is rationally designed based on structural biology, and gL, gH and gp42 proteins of an EB virus are connected through a linker. The antigen of the chimeric design simultaneously stably presents antigen epitopes of the three proteins, can increase the immunogenicity of a vaccine, and can simplify a production amplification process and quality control. The EB virus chimeric antigen can be used alone or in combination with other antigens, has high immunogenicity when used as a vaccine or a vaccine component, can induce an immune animal to produce a high level of neutralizing antibodies, can be used for preparing a vaccine for preventing or treating EB virus infection, and can be used as a detection reagent for the EB virus.

The invention belongs to the technical field of biological medicine, and particularly relates to a bispecific antibody targeting EB virus and application of the bispecific antibody. The invention provides a bispecific antibody targeting EB virus, the bispecific antibody comprises 9G01, 9G02 and 9G03, IC50 of the 9G01, 9G02 and 9G03 in an RAJI B cell infection model is 4.268 * 10 <-6 > mu g / mL, 0.02 mu g / mL and 0.014 mu g / mL respectively, the bispecific antibody can significantly inhibit EB virus infection on epithelial cells and B cells, the neutralization efficiency is further improved, and the EB virus targeted bispecific antibody can be used for preparing a drug for treating EB virus infection. The probe can be used for detecting EB virus, diagnosing diseases caused by EB virus infection, preventing EB virus infection and / or treating and / or preventing diseases caused by EB virus infection.

The application belongs to the technical field of biological medicine, and particularly relates to a nasopharyngeal carcinoma high-risk EB virus strain analysis detection kit and a method and application thereof. The application relates to the technical field of EBV detection. The application reports three unreported nasopharyngeal carcinoma high-risk EB virus SNPs A7001T / A7012G / A7016T, and highly links to the previously reported T6999G highly linked target EBV EBER2. According to the above finding, the application develops a nasopharyngeal carcinoma high-risk EB virus strain rapid typing detection technology, which comprises the following components: a universal primer, a fluorescent probe, NTC, a wild-type quality control product and a mutant quality control product. The technology provided by the application can realize quantitative and typing detection of the nasopharyngeal carcinoma high-risk EB virus strain, and the lower limit of detection is 156 copies / mL of plasma.